Ilya Pharma has announced that Oskar Lund has been appointed Chief Financial Officer.
Lund joins at a pivotal stage in the company’s development as it eyes a potential IPO following recent positive results from the first in human (FIH) trial of its lead candidate ILP100 for treating difficult and chronic wounds, the company states.
“Oskar is a key addition to the team as we enter a new phase of company development following the recently released FIH data,” says Evelina Vågesjö, Ilya Pharma’s CEO. “I look forward to working with him on our ambitious strategy and major upcoming financing rounds including a possible IPO.”
A strong track record of fund raising combined with in-depth financial management and strategic business development experience
Lund comes to Ilya from Disruptive Materials, another Uppsala-based life sciences startup, having engineered the strategic split of the company into two groups along with a c-round funding of the newly spun-out pharma business. This is backed by a strong track record of fund raising combined with in-depth financial management and strategic business development experience in the private, corporate and public sectors, including GE, BNP Paribas and JP Morgan, states Ilya Pharma.
“I am delighted to join Ilya Pharma at this exciting stage in the company’s development. The underlying technology offers multiple opportunities for accelerated and sustained growth. I look forward to leveraging both my extensive Nordic and US networks and recent experience with Disruptive Materials in securing the capital and diverse shareholder base with an institutional focus to achieve this,” says Oskar Lund.
Photo of Oskar Lund: ilyapharma.se
